San Diego Life Sciences Roundup: Halozyme, Skylight, NuSI, & More

9/27/12Follow @bvbigelow

Halozyme Therapeutics got a shot in the arm after the FDA decided that safety concerns over the company’s recombinant enzyme were limited to its drug program with Baxter. Here’s my rundown, along with the rest of San Diego’s life sciences news.

—The FDA allowed San Diego’s Halozyme Therapeutics (NASDAQ: HALO) and Exton, PA-based ViroPharma (NASDAQ: VPHM) to resume clinical trials of a joint product they’re developing for a rare immune disorder. The FDA on Aug. 2 halted testing of the drug, which combines ViroPharma’s C1 esterase inhibitor (Cinryze) with Halozyme’s proprietary recombinant human hyaluronidase, or rHuPH20. The FDA had halted the trials due to safety concerns over antibodies to rHuPH20 that were detected in tests of another experimental drug called HyQ, which combines Baxter’s disease-fighting immunoglobulin Halozyme rHuPH20. Halozyme said the FDA’s concerns are now limited specifically to the HyQ program.

—I got a chance to talk briefly with Peter Attia, president of the new San Diego Nutrition Science Initiative (NuSI), who told me the kind of exacting research he wants to do will require the use of metabolic chambers. Attia said he’s considering acquiring as many as eight of the chambers, and creating a facility for patients that would be much like a hotel—so they’re actually pleasant to be in.

—The San Diego-based West Health Institute said it used Microsoft’s Kinect motion sensing … Next Page »

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.